Synopsis: Fabtech Technologies’ stock rose over 10% after securing a Rs. 31.23 crore international contract to build a Veterinary Vaccine Manufacturing Facility in Botswana. The strategic engineering project extends the company’s African expansion and lifts its unexecuted order book to Rs. 1,440 crore.
Fabtech Technologies Limited has entered investor focus after announcing a major international order win that strengthens its growing footprint in Africa’s healthcare infrastructure sector. Following the announcement, the stock gained nearly 10%, trading around Rs. 161 on June 16, while touching an intraday high of Rs. 165 as positive sentiment built around the overseas contract.
In a regulatory filing dated June 15, 2026, the company announced that it has secured a Rs. 31.23 crore contract for the internal infrastructure scope of a new Veterinary Vaccine Manufacturing Facility in Botswana. Under the project, Fabtech will deliver GMP-compliant internal infrastructure, advanced HVAC systems, clean utilities, and critical MEP services designed to meet global vaccine manufacturing standards. The project will support large-scale veterinary vaccine production and strengthen healthcare manufacturing capacity across Southern Africa.
The order is strategically significant as Africa is rapidly expanding local vaccine manufacturing capabilities after supply chain disruptions exposed during the COVID-19 pandemic. The African Union has set an ambitious target of producing 60% of the continent’s vaccine requirements locally by 2040, creating a large long-term opportunity for companies involved in pharmaceutical infrastructure development. By securing this contract, Fabtech continues building strategic engineering references that could position it for larger pharmaceutical and human vaccine facility projects in the region.
The Botswana contract further strengthens Fabtech’s already robust order pipeline. As of June 2026, the company’s unexecuted order book stands at a record Rs. 1,440 crore, providing revenue visibility for nearly the next two years. This marks the company’s fourth major African contract in the past 12 months, following earlier projects in Egypt and Kenya, highlighting management’s aggressive international expansion strategy.
Financial performance has also remained strong. For FY26, Fabtech reported 38% year-on-year revenue growth to Rs. 842 crore, while net profit surged 52% to Rs. 78 crore, driven by higher margins from international turnkey infrastructure projects. International business now contributes nearly 62% of total revenue, up sharply from 45% two years ago, showing how overseas markets are becoming central to the company’s growth strategy.
With a market capitalization of around Rs. 715 crore and trading at Rs. 161 well balanced within its 52-week range of Rs. 126 to Rs. 263 Fabtech is increasingly being viewed as a niche high-growth player in life sciences infrastructure. As global demand rises for vaccine manufacturing facilities, clean utilities, and GMP-compliant pharmaceutical infrastructure, the company’s latest Rs. 31.23 crore contract with the Botswana Vaccine Institute further strengthens Fabtech’s long-term international growth outlook and keeps the stock firmly on investors’ radar.
Company Overview
Fabtech Technologies Limited is a leading life sciences infrastructure and engineering company specializing in turnkey pharmaceutical plant solutions. The company provides end-to-end services encompassing design, cleanroom engineering, advanced HVAC systems, and global GMP-compliant manufacturing setup to biotechnology, pharmaceutical, and healthcare providers globally.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
